Neurolief, a pioneering brain stimulation company specialising in non-invasive neuromodulation therapies, announced a strategic investment from BrainsWay Ltd, a publicly-traded global leader in non-invasive neurostimulation treatments for mental health disorders. This investment marks a significant milestone as Neurolief awaits FDA approval and prepares for the commercial launch of its ProlivRx, designed for the treatment of Major Depressive Disorder (MDD). The partnership reflects an exciting strategic alignment between the two companies, both of which are dedicated to expanding access to innovative, clinically validated and non-invasive mental health treatments.
"We are on the brink of introducing an entirely new category in neuromodulation - bringing at-home treatment for major depressive disorder," said Scott Drees, Chief Executive Officer at Neurolief. "With BrainsWay's commercial expertise and the global reach of its proprietary Deep TMS system deployed in over 1,500 clinics globally, we are well-positioned to scale following our pending FDA approval and deliver a much-needed therapeutic solution for the millions affected by this debilitating condition."
Major Depressive Disorder remains one of the most prevalent and burdensome mental health conditions worldwide. A significant subset of patients fails to respond adequately to traditional treatments such as antidepressant medications, resulting in prolonged illness, increased healthcare costs, and heightened risks of comorbidities, including substance use disorders and suicide. The lack of adequately accessible therapies for these patients highlights a critical gap in mental health care, emphasising the urgent need for innovative and effective treatment strategies. ProlivRx is designed to bridge this gap by offering a revolutionary, non-invasive brain neuromodulation therapy that can be administered at a mental health clinic or a patient's home. By delivering effective brain stimulation through a wearable at-home therapy, Neurolief offers a fundamentally different approach - one that has the potential to radically shift how major depressive disorder is treated and address the unmet needs of patients who did not achieve improvement with traditional treatments.
